Keyphrases
Acute Decompensated Heart Failure
100%
HbA1c Levels
100%
Heart Failure Patients
100%
Type 2 Diabetes Mellitus (T2DM)
100%
Type 2 Diabetic Patients
100%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
100%
Type 2 Diabetic Mellitus
57%
Urine Volume
42%
Hemoglobin A1c (HbA1c)
28%
Urinary Glucose Excretion
28%
Heart Failure
14%
Clinical Parameters
14%
B-type Natriuretic Peptide
14%
Initial Management
14%
Chronic Heart Failure
14%
Heart Failure Management
14%
Heart Failure Events
14%
Worsening Heart Failure
14%
Canagliflozin
14%
Empagliflozin
14%
Asymptomatic Hypoglycemia
14%
Urine Output
14%
Heart Failure Trials
14%
Urine Excretion
14%
Medicine and Dentistry
Hemoglobin A1c
100%
Maturity Onset Diabetes of the Young
100%
Patient with Type 2 Diabetes
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Decompensated Heart Failure
100%
Congestive Heart Failure
83%
Diabetes Mellitus
66%
Brain Natriuretic Peptide
16%
Hypoglycemia
16%
Glucosuria
16%
Empagliflozin
16%
Canagliflozin
16%
Nursing and Health Professions
Hemoglobin A1c
100%
Patient with Type 2 Diabetes
100%
Congestive Heart Failure
100%
Non Insulin Dependent Diabetes Mellitus
100%
Sodium Glucose Cotransporter 2 Inhibitor
66%
Diabetes Mellitus
44%
Urine Volume
44%
Glucose Urine Level
22%
Brain Natriuretic Peptide
11%
Hypoglycemia
11%
Glucosuria
11%
Empagliflozin
11%
Canagliflozin
11%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
100%
Hemoglobin A1c
100%
Non Insulin Dependent Diabetes Mellitus
100%
Sodium Glucose Cotransporter 2 Inhibitor
66%
Diabetes Mellitus
44%
Brain Natriuretic Peptide
11%
Hypoglycemia
11%
Glucosuria
11%
Canagliflozin
11%
Empagliflozin
11%
Neuroscience
Diabetes Mellitus
100%
Hemoglobin A1c
100%
Sodium Glucose Cotransporter 2
100%
Brain Natriuretic Peptide
16%
Canagliflozin
16%
Hypoglycemia
16%